Attached files
file | filename |
---|---|
EX-23.1 - EX-23.1 - Deciphera Pharmaceuticals, Inc. | d597780dex231.htm |
EX-5.1 - EX-5.1 - Deciphera Pharmaceuticals, Inc. | d597780dex51.htm |
As filed with the Securities and Exchange Commission on June 6, 2018.
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-1
REGISTRATION STATEMENT
Under
The Securities Act of 1933
DECIPHERA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 2834 | 30-1003521 | ||
(State or other jurisdiction of incorporation or organization) |
(Primary Standard Industrial Classification Code Number) |
(I.R.S. Employer Identification Number) |
500 Totten Pond Road
Waltham, MA 02451
(781) 209-6400
(Address, including zip code, and telephone number, including area code, of registrants principal executive offices)
Michael D. Taylor, Ph.D.
President & Chief Executive Officer
500 Totten Pond Road
Waltham, MA 02451
(781) 209-6400
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Richard A. Hoffman, Esq. Edwin M. OConnor, Esq. Goodwin Procter LLP 100 Northern Avenue Boston, Massachusetts 02210 (617) 570-1000 |
Richard D. Truesdell Jr., Esq. Marcel R. Fausten, Esq. Davis Polk & Wardwell LLP 450 Lexington Avenue New York, New York 10017 (212) 450-4000 |
Approximate date of commencement of proposed sale to the public:
As soon as practicable after the effective date of this registration statement.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended, check the following box. ☐
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ File No. 333-225411
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ (Do not check if a smaller reporting company) | Smaller reporting company | ☐ | |||
Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒
CALCULATION OF REGISTRATION FEE
| ||||
Title of Each Class of Securities to be Registered |
Proposed Maximum Aggregate Offering Price(1) |
Amount of Registration Fee(2) | ||
Common Stock, par value $0.01 per share |
$32,588,125 | $4,058 | ||
| ||||
|
(1) | In accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended, the Registrant is registering an additional amount of securities having a proposed maximum offering price of no more than 20% of the maximum aggregate offering price of the securities eligible to be sold under the related Registration Statement on Form S-1, as amended (File No. 333-225411). Includes the aggregate offering price of shares that may be purchased by the underwriters pursuant to an option to purchase additional shares. |
(2) | Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. Includes the aggregate offering price of shares that may be purchased by the underwriters pursuant to an option to purchase additional shares. |
This Registration Statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) promulgated under the Securities Act.
EXPLANATORY NOTE AND INCORPORATION BY REFERENCE
This Registration Statement relates to the public offering of common stock, par value $0.01 per share, of the Registrant contemplated by the Registration Statement on Form S-1 (File No. 333-225411), initially filed with the Securities and Exchange Commission by the Registrant on June 4, 2018 (as amended, the Prior Registration Statement), and is being filed for the sole purpose of registering an increase in the maximum aggregate offering price of $32,588,125 of securities of the same class as were included in the Prior Registration Statement. The contents of the Prior Registration Statement, which was declared effective by the Securities and Exchange Commission on June 6, 2018, and all exhibits thereto are hereby incorporated by reference into this Registration Statement.
The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.
EXHIBIT INDEX
Exhibit No. |
Exhibit Index |
|||
5.1 | Opinion of Goodwin Procter LLP | |||
23.1 | Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm | |||
23.2 | Consent of Goodwin Procter LLP (included in Exhibit 5.1) | |||
24.1** | Power of Attorney |
** | Previously filed. |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Commonwealth of Massachusetts, on June 6, 2018.
DECIPHERA PHARMACEUTICALS, INC. | ||
By: | /s/ Michael D. Taylor | |
Michael D. Taylor, Ph.D. | ||
President and Chief Executive Officer |
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement on Form S-1 has been signed by the following person in the capacities and on the date indicated.
Name |
Title |
Date | ||
/s/ Michael D. Taylor |
President, Chief Executive Officer and Director | |||
Michael D. Taylor, Ph.D. | (Principal Executive Officer) | June 6, 2018 | ||
/s/ Thomas P. Kelly |
Chief Financial Officer | |||
Thomas P. Kelly | (Principal Financial and Accounting Officer) | June 6, 2018 | ||
* |
||||
Patricia L. Allen | Director | June 6, 2018 | ||
* |
||||
Edward J. Benz, Jr., M.D. | Director | June 6, 2018 | ||
* |
||||
James A. Bristol, Ph.D. | Director | June 6, 2018 | ||
* |
||||
Steven L. Hoerter | Director | June 6, 2018 | ||
* |
||||
John R. Martin | Director | June 6, 2018 | ||
* |
||||
Liam Ratcliffe, M.D., Ph.D | Director | June 6, 2018 | ||
* |
||||
Michael Ross, Ph.D | Director | June 6, 2018 | ||
* |
||||
Dennis L. Walsh | Director | June 6, 2018 |
*By: | /s/ Michael D. Taylor |
|||||||
Michael D. Taylor, Ph.D. | Attorney-in-fact | June 6, 2018 |